Surgery Reduces Prostate-Cancer Mortality
Posted on: Thursday, 19 April 2007, 15:00 CDT
Surgery reduced the 15-year mortality rate of prostate cancer by 59 percent overall, according to preliminary U.S. study data.
The overall survival advantage was 8.6 years and was 6.8, 5.5 and 10.4 years for patients with grade 1, 2 and 3 disease, respectively, according to the report in the journal Urology.
Randomized studies comparing conservative therapy to definitive therapy in men with prostate cancer are under way but not yet available. However, Dr. Ashutosh Tewari of the Weill Medical College of Cornell University analyzed the outcomes of 3,159 U.S. men treated either conservatively or with radiotherapy or radical prostatectomy -- prostate removal -- from 1980 to 1997.
Radiotherapy patients also experienced a survival advantage with a reduction in mortality of 33 percent. Radiotherapy or prostate removal reduced the death rate from prostate cancer by 38 percent and 63 percent, respectively, compared with patients treated conservatively.
Source: United Press International
Related Articles
- Chemo-Radiation Before Prostate Removal May Prevent Cancer Recurrence
- Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
- Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
- Introgen Presents Biomarker Data Demonstrating Abnormal P53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers
- VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates As High As 54 Percent in Patients With Previously Treated Multiple Myeloma
- Colon-Tested Patients Cancer-Free at 5 Yrs
- Mathematical Model Predicts That CERVARIX May Prevent Nearly 80 Percent of Cervical Cancers
- Preliminary Topline Efficacy Results From Phase II Data Show Macugen(R) (Pegaptanib Sodium Injection) Maintained or Improved Vision in Over 90 Percent of Patients With Macular Edema Associated With Central Retinal Vein Occlusion (CRVO)
- The Four Major Cancer Markets, Which Include Colorectal, Prostate, Lung and Breast Cancer, Were Valued at Well Over $16 Billion in 2005
- Up to 40 Percent of Patients With Some Cancers Are at Risk of Sneaky Secondary Threat
 |
 |
User Comments (0)
RSS Feeds